[
    {
        "id": "osp-13072",
        "type": "article-journal",
        "title": "Bevacizumab therapy for macular edema in central retinal vein occlusion: Long-term results",
        "author": [
            {
                "family": "Manayath",
                "given": "George J"
            },
            {
                "family": "Narendran",
                "given": "V"
            },
            {
                "family": "Al-Kharousi",
                "given": "Nadia"
            },
            {
                "family": "Wali",
                "given": "Upender K."
            }
        ],
        "URL": "https://omanscience.com/en/articles/bevacizumab-therapy-for-macular-edema-in-central-retinal-vein-occlusion-long-term-results",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2009
                ]
            ]
        },
        "container-title": "Oman Journal of Ophthalmology",
        "volume": "2",
        "issue": "2",
        "page": "73-78",
        "DOI": "10.4103/0974-620x.53036",
        "publisher": "Medknow Publications",
        "ISSN": "0974-620X",
        "abstract": "Background: There is no proven effective treatment for vision loss in central retinal vein occlusion (CRVO). Bevacizumab has been reported in small series with limited follow-up, to have a positive effect in reducing cystoid macular edema (CME) and improving vision in CRVO.\n\nPurpose: To report long-term results with the use of bevacizumab in CRVO.\n\nMaterials and methods: Prospective interventional case series included 15 patients, serially evaluated with best corrected visual acuity (BCVA), optical coherence tomography (OCT), fluorescein angiography, and tonometry. Results were statistically analyzed.\n\nResults: Mean follow-up was 12 +/- 3.6 months (range, 6-18 months); mean number of injections was 2.2 (range, 1-4) per patient. Statistically significant reduction of macular thickness (P < 0.001) was seen at six weeks (mean, 346 mu); three months (mean, 353 mu); six months (mean, 348 mu); and final follow-up (mean, 342 mu). Significant BCVA improvement was seen at six weeks (mean, 0.27 logMAR), three months (mean, 0.3 logMAR), three months (0.15 logMAR), and final follow-up (mean, 0.21 logMAR) (P = 0.009). Also, 73.3% patients had BCVA improvement at the last follow-up.\n\nConclusion: Intravitreal bevacizumab is an effective treatment option for CME in CRVO patients. Reinjections at appropriate timing, based on the OCT findings, are important for better visual outcome."
    }
]